 Artist: Robert Wyatt: mp3 download Genre(s): Rock Other Discography:  Comicopera Year: 2007 Tracks: 16  Rock Bottom Year: 2004 Tracks: 6  Ruth Is Stranger Than Richard Year: 1998 Tracks: 9  Shleep (with Brian Eno) Year: 1997 Tracks: 11  The End of an Ear Year: 1970 Tracks: 9 An enduring fig wHO came to prominence in the early years of the English artistry john Rock and roll aspect, Robert Wyatt has produced a significant body of do work, both as the original drummer for graphics rockers Soft Machine and as a radical political singer/songwriter. Born in Bristol, England, Wyatt came to Soft Machine during the exciting, slimly post-psychedelic Canterbury Scene of the mid-'60s that produced bands care Gong and Pink Floyd. Unlike many of the fine artwork john Rock bands that would do by and by (Jethro Tull, Yes, King Crimson), Soft Machine eschewed bloated theatrical excess, preferring a standard rock 'n' pluck format that interpolated jazz riffing, extended soloing, and some forays into data-based noise. Wyatt, so Soft Machine's drummer, left manus the band during its initial waving of popularity. His solo career was reinforced less about his abilities as a percussionist and more than more or less his fallible tenor spokesperson voice, capable of breakage black Maria with its falsetto range. It was not long subsequently his number one solo outlet, End of an Ear, that Wyatt fell from an open window during a party, fracturing his second and for good paralyzing him from the waistline down. After months of awful convalescence, Wyatt reemerged with the excruciating Rock and roll Bottom (1974) and the freaky Babe Ruth Is Stranger Than Richard (1975), the late dealing explicitly with his post-accident life, the latter a series of phantasmagorical fables. And piece the music on these records is trancelike and experimental, Wyatt shockingly recorded a straight version of the Monkees' "I'm a Believer" in 1974 that became a braggart British hit. Controversy ensued when the BBC's long-running weekly bulge out music program Top of the Pops refused to allow Wyatt to perform the vocal in his wheelchair. After a significant protestation played out in the music trade papers, Wyatt did perform. Despite his success, Wyatt remained quiet for practically of the rest of the x, breaking his silence during the punk epoch with a handful of singles recorded for the capital English indie label Rough Trade. Again, departure against audience expectations, he recorded a beautiful adaptation of Chic's "At Last I Am Free." This signaled the begin of a fully fledged career renaissance that included legion albums and artists such as Elvis Costello writing songs for him. His albums were lush, at times well-nigh broody, and Wyatt's voice -- solve, emotionally supercharged, and always on the sceptre of breaking -- brought nifty depth and soul to songs that, if recorded by a lesser artist, would have sounded terse and tired. Always on the political left field, Wyatt's radicalism increased exponentially during Margaret Thatcher's years as Prime Minister, as he retained an unwavering support for Communism even as glasnost was near. The resulting music he recorded during this period reflects his strong, bordering on strident, political beliefs. As of the mid-2000s, Wyatt has comfortably worked in and out of the music business. He records when he feels like it, paints, writes, devotes time to political work on, and continues to testify no interest group in the machinations of the music industry. But, despite his now and then blatant political posture, he has recorded some stunning music, full of curiosity, possibility, and arrant emotion, that remains undiscovered by many. |
Friday 22 August 2008
Download Robert Wyatt mp3
Tuesday 12 August 2008
Bob Lind
Artist: Bob Lind
Genre(s):
Other
Rock
Discography:
Elusive Butterfly
Year: 2007
Tracks: 1
Since There Were Circles
Year: 2006
Tracks: 11
Don't Be Concerned
Year: 1966
Tracks: 12
Bob Lind's "Elusive Butterfly" was one of the to the highest degree successful one-shots of the mid-'60s folk-rock boom, stretch the Top Five in early 1966. He ne'er came close to matching that early crow, although other acts brought his songs to a wider hearing with their covers of Lind compositions like "Cheryl's Going Home" (Vapors Project), "Counting" (Marianne Faithfull), and "Mr. Zero" (Yardbirds' lead story vocaliser Keith Relf). The dish of Jack Nitzsche's intricate production on Lind's two 1966 LPs, favoring acoustic guitars and pretty string arrangements, is admirable, simply Lind himself hasn't raddled that well. His songs ar verbose and on the didactical incline; his vocalism is nervous and lacks emotional range; his melodies are pretty, only non enormously so.
Vicente One More Time
Wednesday 6 August 2008
Angelina Jolie & Brad Pitt's Shock & Awe Over Twins
Angelina Jolie and Brad Pitt experience told of their astonished reaction to finding out they were expecting twins.
The superstar couple increased their brood to six with the
Targacept Starts Phase 2b Clinical Trial Of TC-5214 As Augmentation Treatment In Major Depressive Disorder
�Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing a new year of drugs known as NNR Therapeutics�, today proclaimed that it has initiated a Phase 2b clinical trial of TC-5214 as an augmentation therapy in subjects with Major Depressive Disorder (MDD). TC-5214 is a wide spectrum neural nicotinic sense organ (NNR) antagonist and represents a hopeful new mechanism in growing for the treatment of MDD.
"The millions of patients distress from depression who do not respond well to the presently available first-line therapies need help," said Dr. Madhukar H. Trivedi, Professor and the Director of the Mood Disorders Research Program and Clinic at the University of Texas Southwestern Medical Center at Dallas and 1 of the principal investigators in the National Institute of Mental Health's large-scale STAR*D study. "There is a great unmet medical need for effective second and third line treatments with novel mechanisms of action to augment existing therapies and improve clinical outcomes for these patients. I am very enthusiastic about the potential for NNR-targeted compounds and other novel mechanisms to serve this need."
The design of the Phase 2b trial of TC-5214 includes two phases. In the first stage, subjects diagnosed with MDD will receive citalopram hydrobromide, a selective serotonin reuptake inhibitor (SSRI), for 8 weeks to determine the extent of therapeutic response. Subjects world Health Organization have non responded well based on predefined criteria would be randomized into the double blind sec phase of the run and receive either TC-5214 or placebo, together with continued citalopram therapy, for an extra eight weeks. It is expected that approximately 560 subjects will participate in the first phase of the run and close to 220 subjects will be randomized into the moment phase of the trial. The master endpoint of the trial run is change from baseline during the second stage of the trial as measured by the Hamilton Depression Rating Scale. The trial volition also collect information on a variety of lower-ranking safety and efficacy measures. The trial is planned to be conducted at sites in the United States and India.
"The initiation of this Phase 2b clinical trial, just four months after TC-5214 initially entered the clinic, reflects non only our enthusiasm for its curative promise but also our ability to execute against a very aggressive development plan," aforesaid J. Donald deBethizy, Ph.D., President and Chief Executive Officer of Targacept. "We believe that the favourable preclinical visibility of TC-5214, combined with the positive results from our premature Phase 2 clinical trial run of mecamylamine as an augmentation treatment for MDD, bode well for TC-5214's potential for clinical success."
About TC-5214
It is well known that depressive symptoms canful result from an overstimulation of NNRs and early receptors in the brainiac that ar activated by the neurotransmitter acetylcholine. Accordingly, compounds capable of inhibiting the action of these overstimulated receptors, known as antagonists, may be expected to have antidepressant effects. In a prior Phase 2 clinical trial conducted by Targacept, subjects with MDD whose treatment with citalopram was augmented with mecamylamine hydrochloride showed greater improvement on symptoms of depression than subjects world Health Organization received continued citalopram treatment and placebo.
TC-5214 is the S(+) enantiomer of mecamylamine hydrochloride. TC-5214 has exhibited an overall therapeutical profile superior to mecamylamine in presymptomatic models of depression and anxiety (Lippiello et al., accepted for publication in CNS Neuroscience & Therapeutics), a determination consistent with laboratory studies showing TC-5214 to more effectively inhibit the body process of the alpha4beta2 NNR.
About MDD
According to The National Institute of Mental Health, MDD is the star cause of disability in the United States for people between the ages 15 and 44. The NIMH estimates that close to 14.8 million American adults suffer from MDD.
The Sequenced Treatment Alternatives to Relieve Depression, or STAR*D, study undertaken by the National Institute of Mental Health between 2001 and 2006 showed the inadequacy of currently available therapies for MDD. In the low phase of the STAR*D study, roughly 2,800 persons with MDD were given citalopram for 12 to 14 weeks. Only about one-third of the participants reached remission and about 10-15 percent more than responded, only did not reach remission. The second phase of the STAR*D study evaluated the effects of augmentation with a new medication or switch to a different discussion for participants who did not respond or only when responded partially to citalopram. Approximately unrivalled in little Joe of these participants reached remission. These findings induce been cited as highlight the need for more broadly effective antidepressant treatments (Rush, et al., NEJM Volume 354:1231-1242, March 23, 2006 Number 12).
About Targacept
Targacept is a clinical-stage biopharmaceutical troupe that discovers and develops NNR Therapeutics�, a new class of drugs for the treatment of central nervous organisation diseases and disorders. Targacept's product candidates selectively modulate neuronal nicotinic receptors that serve as key regulators of the nervous system to promote therapeutic effects and limit adverse side effects. Targacept has product candidates in development for Alzheimer's disease, cognitive dysfunction in schizophrenic disorder, pain and depression, as well as multiple presymptomatic programs. Targacept also has a cognition-focused collaboration with AstraZeneca and a strategic alliance with GlaxoSmithKline. Targacept's news releases are available on its website at www.targacept.com.
Forward-Looking Statements
Statements in this press waiver that are not strictly historical in nature, including, without limitation, statements regarding the advancement, timing or scope of the research and development of TC-5214 or related regulatory filings or clinical trials, including the number of subjects to be included in the on-going Phase 2b trial, the benefits that may be derived from TC-5214, our plans, expectations, future operations, financial place, revenues, costs or expenses, constitute "advanced statements" within the substance of the Private Securities Litigation Reform Act of 1995. Actual results crataegus laevigata differ materially from those expressed or implied by forward-looking statements as a result of various important factors, including risks and uncertainties relating to: the results of clinical trials and non-clinical studies and assessments with respect to TC-5214, including whether the results of our realized Phase 2 clinical test of racemic mecamylamine as an augmentation treatment for MDD and positive findings in preclinical studies of TC-5214 ar predictive of the results of the ongoing Phase 2b clinical trial and any future clinical trials of TC-5214; the conduct of such trials, studies and assessments, including the performance of third parties that we engage to execute them and difficulties or delays in the completion of subject enrollment or information analysis; the timing and success of submission, acceptance and favorable reception of regulative filings with respect to TC-5214; our ability to obtain, hold and enforce patent security for TC-5214; and our ability to obtain material additional financing. These and other risks and uncertainties that crataegus laevigata impact real results ar described in greater detail under the heading "Risk Factors" in our most recent Annual Report on Form 10-K and in other filings that we make with the Securities and Exchange Commission. As a consequence of the risks and uncertainties, the ts or events indicated by the forward-looking statements may non occur. We caution you not to place undue reliance on any modern statement. In addition, whatsoever forward-looking statements in this release constitute our views only as of the date of this outlet and should not be relied upon as representing our views as of any subsequent date. We anticipate that subsequent events and developments may cause our views to change. Although we may elect to update these forward-looking statements publicly at some point in the future, we specifically disclaim any obligation to do so, except as required by applicable constabulary.
Source
Alan Musso
Targacept, Inc., VP and CFO
www.targacept.com
More info
"The millions of patients distress from depression who do not respond well to the presently available first-line therapies need help," said Dr. Madhukar H. Trivedi, Professor and the Director of the Mood Disorders Research Program and Clinic at the University of Texas Southwestern Medical Center at Dallas and 1 of the principal investigators in the National Institute of Mental Health's large-scale STAR*D study. "There is a great unmet medical need for effective second and third line treatments with novel mechanisms of action to augment existing therapies and improve clinical outcomes for these patients. I am very enthusiastic about the potential for NNR-targeted compounds and other novel mechanisms to serve this need."
The design of the Phase 2b trial of TC-5214 includes two phases. In the first stage, subjects diagnosed with MDD will receive citalopram hydrobromide, a selective serotonin reuptake inhibitor (SSRI), for 8 weeks to determine the extent of therapeutic response. Subjects world Health Organization have non responded well based on predefined criteria would be randomized into the double blind sec phase of the run and receive either TC-5214 or placebo, together with continued citalopram therapy, for an extra eight weeks. It is expected that approximately 560 subjects will participate in the first phase of the run and close to 220 subjects will be randomized into the moment phase of the trial. The master endpoint of the trial run is change from baseline during the second stage of the trial as measured by the Hamilton Depression Rating Scale. The trial volition also collect information on a variety of lower-ranking safety and efficacy measures. The trial is planned to be conducted at sites in the United States and India.
"The initiation of this Phase 2b clinical trial, just four months after TC-5214 initially entered the clinic, reflects non only our enthusiasm for its curative promise but also our ability to execute against a very aggressive development plan," aforesaid J. Donald deBethizy, Ph.D., President and Chief Executive Officer of Targacept. "We believe that the favourable preclinical visibility of TC-5214, combined with the positive results from our premature Phase 2 clinical trial run of mecamylamine as an augmentation treatment for MDD, bode well for TC-5214's potential for clinical success."
About TC-5214
It is well known that depressive symptoms canful result from an overstimulation of NNRs and early receptors in the brainiac that ar activated by the neurotransmitter acetylcholine. Accordingly, compounds capable of inhibiting the action of these overstimulated receptors, known as antagonists, may be expected to have antidepressant effects. In a prior Phase 2 clinical trial conducted by Targacept, subjects with MDD whose treatment with citalopram was augmented with mecamylamine hydrochloride showed greater improvement on symptoms of depression than subjects world Health Organization received continued citalopram treatment and placebo.
TC-5214 is the S(+) enantiomer of mecamylamine hydrochloride. TC-5214 has exhibited an overall therapeutical profile superior to mecamylamine in presymptomatic models of depression and anxiety (Lippiello et al., accepted for publication in CNS Neuroscience & Therapeutics), a determination consistent with laboratory studies showing TC-5214 to more effectively inhibit the body process of the alpha4beta2 NNR.
About MDD
According to The National Institute of Mental Health, MDD is the star cause of disability in the United States for people between the ages 15 and 44. The NIMH estimates that close to 14.8 million American adults suffer from MDD.
The Sequenced Treatment Alternatives to Relieve Depression, or STAR*D, study undertaken by the National Institute of Mental Health between 2001 and 2006 showed the inadequacy of currently available therapies for MDD. In the low phase of the STAR*D study, roughly 2,800 persons with MDD were given citalopram for 12 to 14 weeks. Only about one-third of the participants reached remission and about 10-15 percent more than responded, only did not reach remission. The second phase of the STAR*D study evaluated the effects of augmentation with a new medication or switch to a different discussion for participants who did not respond or only when responded partially to citalopram. Approximately unrivalled in little Joe of these participants reached remission. These findings induce been cited as highlight the need for more broadly effective antidepressant treatments (Rush, et al., NEJM Volume 354:1231-1242, March 23, 2006 Number 12).
About Targacept
Targacept is a clinical-stage biopharmaceutical troupe that discovers and develops NNR Therapeutics�, a new class of drugs for the treatment of central nervous organisation diseases and disorders. Targacept's product candidates selectively modulate neuronal nicotinic receptors that serve as key regulators of the nervous system to promote therapeutic effects and limit adverse side effects. Targacept has product candidates in development for Alzheimer's disease, cognitive dysfunction in schizophrenic disorder, pain and depression, as well as multiple presymptomatic programs. Targacept also has a cognition-focused collaboration with AstraZeneca and a strategic alliance with GlaxoSmithKline. Targacept's news releases are available on its website at www.targacept.com.
Forward-Looking Statements
Statements in this press waiver that are not strictly historical in nature, including, without limitation, statements regarding the advancement, timing or scope of the research and development of TC-5214 or related regulatory filings or clinical trials, including the number of subjects to be included in the on-going Phase 2b trial, the benefits that may be derived from TC-5214, our plans, expectations, future operations, financial place, revenues, costs or expenses, constitute "advanced statements" within the substance of the Private Securities Litigation Reform Act of 1995. Actual results crataegus laevigata differ materially from those expressed or implied by forward-looking statements as a result of various important factors, including risks and uncertainties relating to: the results of clinical trials and non-clinical studies and assessments with respect to TC-5214, including whether the results of our realized Phase 2 clinical test of racemic mecamylamine as an augmentation treatment for MDD and positive findings in preclinical studies of TC-5214 ar predictive of the results of the ongoing Phase 2b clinical trial and any future clinical trials of TC-5214; the conduct of such trials, studies and assessments, including the performance of third parties that we engage to execute them and difficulties or delays in the completion of subject enrollment or information analysis; the timing and success of submission, acceptance and favorable reception of regulative filings with respect to TC-5214; our ability to obtain, hold and enforce patent security for TC-5214; and our ability to obtain material additional financing. These and other risks and uncertainties that crataegus laevigata impact real results ar described in greater detail under the heading "Risk Factors" in our most recent Annual Report on Form 10-K and in other filings that we make with the Securities and Exchange Commission. As a consequence of the risks and uncertainties, the ts or events indicated by the forward-looking statements may non occur. We caution you not to place undue reliance on any modern statement. In addition, whatsoever forward-looking statements in this release constitute our views only as of the date of this outlet and should not be relied upon as representing our views as of any subsequent date. We anticipate that subsequent events and developments may cause our views to change. Although we may elect to update these forward-looking statements publicly at some point in the future, we specifically disclaim any obligation to do so, except as required by applicable constabulary.
Source
Alan Musso
Targacept, Inc., VP and CFO
www.targacept.com
More info
Subscribe to:
Posts (Atom)